Amylyx Pharmaceuticals, Inc. Common Stock
AMLX Real Time Price USDRecent trades of AMLX by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Chris Jacobs House / R | Purchase $1,001 - $15,000 | Oct. 12, 2022 |
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by AMLX's directors and management
Government lobbying spending instances
-
$40,000 Oct 18, 2024 Issue: Medicare/Medicaid Health Issues
-
$80,000 Jul 15, 2024 Issue: Medicare/Medicaid Health Issues
-
$80,000 Apr 16, 2024 Issue: Medicare/Medicaid Health Issues
-
$80,000 Feb 07, 2024 Issue: Medicare/Medicaid Health Issues
-
$80,000 Jan 20, 2024 Issue: Medicare/Medicaid Health Issues
-
$80,000 Oct 17, 2023 Issue: Medicare/Medicaid Health Issues
-
$80,000 Jul 17, 2023 Issue: Medicare/Medicaid Health Issues
-
$80,000 Oct 20, 2022 Issue: Medicare/Medicaid Health Issues
-
$30,000 Jul 19, 2022 Issue: Medicare/Medicaid Health Issues
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Methods and compositions for treating amyotrophic lateral sclerosis Nov. 12, 2024
-
Patent Title: Methods and compositions for treating amyotrophic lateral sclerosis Mar. 26, 2024
-
Patent Title: Compositions of bile acids and phenylbutyrate compounds Feb. 21, 2023
-
Patent Title: Compositions of bile acids and phenylbutyrate compounds Jan. 24, 2023
-
Patent Title: Compositions for improving cell viability and methods of use thereof Jul. 27, 2021
-
Patent Title: Compositions for improving cell viability and methods of use thereof Dec. 08, 2020
-
Patent Title: Compositions for improving cell viability and methods of use thereof Apr. 09, 2019
-
Patent Title: Compositions for improving cell viability and methods of use thereof Jan. 23, 2018
Federal grants, loans, and purchases
- $93,600 2024-03-20 00:00:00 Agency: Department of Veterans Affairs
- $204,837 2024-03-13 00:00:00 Agency: Department of Veterans Affairs
- $56,160 2024-02-27 00:00:00 Agency: Department of Veterans Affairs
- $46,800 2024-02-01 00:00:00 Agency: Department of Veterans Affairs
- $279,718 2023-12-20 00:00:00 Agency: Department of Veterans Affairs
- $93,600 2023-12-15 00:00:00 Agency: Department of Veterans Affairs
- $93,600 2023-11-08 00:00:00 Agency: Department of Veterans Affairs
- $74,880 2023-10-06 00:00:00 Agency: Department of Veterans Affairs
- $748,940 2023-10-01 00:00:00 Agency: Department of Veterans Affairs
- $74,880 2023-08-11 00:00:00 Agency: Department of Veterans Affairs
- $10,584 2023-07-28 00:00:00 Agency: Department of Veterans Affairs
- $74,880 2023-07-20 00:00:00 Agency: Department of Veterans Affairs
- $0 2023-07-06 00:00:00 Agency: Department of Veterans Affairs
- $1,478,874 2023-06-02 00:00:00 Agency: Department of Veterans Affairs
- $31,751 2023-06-02 00:00:00 Agency: Department of Veterans Affairs
- $0 2023-06-01 00:00:00 Agency: Department of Veterans Affairs
- $74,880 2023-05-18 00:00:00 Agency: Department of Veterans Affairs
- $355,679 2023-01-31 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $65,520 2023-01-05 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $0 2023-01-05 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $10,530 2022-12-21 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $0 2022-11-29 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
Estimated quarterly amount awarded from public contracts
Number of mentions of AMLX in WallStreetBets Daily Discussion
Recent insights relating to AMLX
Recent picks made for AMLX stock on CNBC
ETFs with the largest estimated holdings in AMLX
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view AMLX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.